About Us
Meet The Team
Nuevocor’s LMNA gene therapy is based on decades of research into fundamental mechanisms underlying LMNA-associated disease enabled by the development of novel technologies on the part of scientific co-founders Colin Stewart and Brian Burke. Together with the AAV gene therapy and cardiac disease modeling expertise of scientific co-founders Mark Kay and Jianming Jiang respectively, Nuevocor is well-positioned to cure LMNA and other genetic cardiomyopathies, amongst other cardiac diseases.
Yann Chong Tan, PhD
Founding CEO
Extensive experience in the biotech space, successful inventor and entrepreneur who co-founded a Nasdaq-listed biotech, Atreca.
Managing Director, EVX Ventures
Euan Ashley, MD, PhD
Scientific Advisory Board Member
Leading medical geneticist and cardiologist at Stanford University.
Co-founder of Personalis and other companies.
Professor of Medicine and Genetics at Stanford University
Brian Burke, PhD
Scientific Co-Founder
Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex, through the innovative use of microscopic and biochemical technologies.
Research Director at the Agency for Science, Technology and Research, Singapore
Jianming Jiang, PhD
Scientific Co-Founder
Emerging leader in investigating the regulatory mechanisms underlying cardiovascular disease through the use of AAV vectors and other cutting-edge technologies.
Asst. Prof. in Biochemistry at the National University of Singapore
Mark Kay, MD, PhD
Scientific Co-Founder
World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.
Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University
Cheryl Lee
Associate Director,
Project Management
Accumulated experience in research project and funding management as administrative and operations lead for both research grantees and grant funder in the Singapore public sector.
Yin Loon Lee, PhD
Co-Founder and Senior Director, Biology
As a postdoctoral fellow with Brian Burke, investigated mechanism of disease in laminopathies, and contributed to development of Nuevocor's technology.
XQ Lin
Board Member
Seasoned Innovator, Entrepreneur,
and Investor.
Chairman EVX Ventures &
Carmine Therapeutics; CEO Esco Lifesciences
David Russell
Senior Advisor
Expert on viral gene therapy and biology, and genetic manipulation of stem cells. Founded and sold Universal Cells, a biotech company built on technologies developed in his academic lab.
Professor Emeritus of Medicine at University of Washington
Idina Shi, PhD
Associate Director, Operations and Business Development
Combined business development and corporate strategy experience through tenures as biotechnology portfolio manager and science policy official in Singapore government science agency.
Colin Stewart, PhD
Scientific Co-Founder
Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.
Research Director at the Agency for Science, Technology and Research, Singapore
Hendrikje Werner, PhD
Principal Scientist
As a postdoctoral fellow with Colin Stewart, played pre-eminent roles in studies that resulted in Nuevocor’s lead program as well as its target discovery platform.
Weiyi Zhang, PhD
Board Member
Pharma veteran with a wealth of industry experience in drug discovery and innovation.
Managing Director of Boehringer Ingelheim Venture Fund China
Careers
Please visit Nuevocor’s LinkedIn page to view our job listings by clicking here.
When you're ready, please click: